ESR1 and prostate carcinoma: Furthermore, the association between FOXA1 and ER in breast cancer and FOXA1 and androgen receptor (AR) in prostate cancer suggests that expression levels of FOXA1 may influence responsiveness to antihormonal treatment in hormone dependent cancers.